AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own ASM International, you need to believe that its atomic layer deposition and epitaxy tools stay at the heart of leading edge AI and high performance computing chip production. The latest attention on its role in advanced logic and memory supports that view, but does not materially change the near term picture where the key catalyst remains advanced node and HBM spending, and the biggest risk is still cyclicality in equipment orders and a book to bill below 1.
Among recent announcements, ASM’s plan to invest several hundred million euros in a new Almere headquarters and R&D hub stands out, because it is tied to supporting its longer term sales ambition of more than €5,700,000,000 by 2030. For investors watching AI driven demand cycles, this type of capacity and innovation build out helps frame how ASM is positioning itself around future leading edge node ramps rather than just the current order cycle.
Yet beneath the AI excitement, the risk that orders stay subdued and the book to bill remains under pressure is something investors should be aware of...
Read the full narrative on ASM International (it's free!)
ASM International's narrative projects €4.6 billion revenue and €1.1 billion earnings by 2028.
Uncover how ASM International's forecasts yield a €627.47 fair value, a 13% upside to its current price.
Six members of the Simply Wall St Community currently see ASM’s fair value anywhere between €390 and €690, highlighting very different expectations. Against this, the reliance on cyclical chipmaker capex and a recently softer order intake could be just as important for how ASM’s story develops, so it is worth weighing several contrasting views.
Explore 6 other fair value estimates on ASM International - why the stock might be worth 30% less than the current price!
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com